{
    "symbol": "CTMX",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-07 15:17:03",
    "content": " We previously reported encouraging initial data of CX-2029's activity in a Phase 2 expansion study in patients with squamous non-small cell lung cancer, all of whom had received prior treatment with checkpoint inhibitors. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. I think that the question was asked a little earlier, excuse me, a little earlier on regarding the timing and our -- the current status of the 2029 program is that we continue to enroll across, the expansion cohorts, where, as Amy mentioned in her comments, we've been highly focused on getting the lung cancer cohort fully enrolled to really further flesh out that signal that we reported at the end of last year in squamous lung."
}